Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications

International Journal of Colorectal Disease

Volumn 14, Issue 1, 1999, Pages 47-51

  Baert, F J ^a   Rutgeerts, P R ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Monoclonal antibodies; TNF ; Treatment

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AUTOANTIBODY; AZATHIOPRINE; CHLOROTRIANISENE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GAMMA INTERFERON; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 1; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; ESOPHAGUS ULCER; HELPER CELL; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOCYTE DEPLETION; MOUTH ULCER; PATHOGENESIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SERUM SICKNESS; STOMACH LYMPHOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; HUMANS; RESEARCH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033021497     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840050182     Document Type: Article

References (29)

1. Beutler B (1992) The role of tumor necrosis factor. Raven New York
2. Barbara JA, Van Ostade X, Lopez A (1996) Tumor necrosis factor alpha (TNF-α): the good, the bad and the potentially very effective. Immunol Cell Biol 75:434-443
3. Riddle NH (1992) Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr Opin Immunol 4:327-332
4. Plevy SE, Targan SR, Deem RL, Toyoda H (1995) Increased mucosal TNF-α levels and numbers of TNF-α producing cells are unique to Crohn's disease mucosal inflammation. Gastroenterology 106:A754
5. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, McDonald TT (1994) Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466
6. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT (1992) Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89-91
7. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709
8. Lukacs NW, Chensue SW, Strieter R, Warmington K, Kunkel SL (1994) Inflammatory granuloma formation is mediated by TNF-α inducible intercellular adhesion molecule-1. J Immunol 152:5883-5889
9. Black RA, Rauch CT, Kozlosky CJ, et al (1997) A metalloproteinase disintegrin that releases tumour necrosis factor alpha from cells. Nature 385:729-733
10. Moss ML, Jin SL, Milla ME, et al (1997) Cloning of a desintegrin metalloproteinase that processes precursor tumour necrosis factor alpha. Nature 385:733-736
11. Noguchi M, Hiwatashi N, Liu Z, Toyota T (1998) Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut 43:203-209
12. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF kappa beta abrogates established experimental colitis in mice. Nat Med 2:998-1004
13. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Arevalo Moore M, Vilcek J, Daddona P, Ghrayeb J (1993) Construction and initial characterization of a mouse-human anti-TNF-antibody. Mol Immunol 30: 1443-1453
14. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilcek J, Dadonna PE (1995) The mouse/ human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo. Cytokine 7:15-25
15. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7:251-259
16. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. New Engl J Med 334: 1717-1725
17. Mohler KM, Torrance DS, Smith CA, et al (1993) Soluble tumor necrosis factor alpha (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneous-ly as both TNF carriers and TNF antagonists. J Immunol 151 : 1548-1561
18. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S (1997) Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependant chronic active Crohn's disease. Gut 40:470-474
19. Wettstein AR, Meagher AP (1997) Thalidomide in Crohn's disease. Lancet 350:1445-1446
20. Odeka EB, Miller V (1997) Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 25:250-251
21. Van Dullemen HM, van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Woody J (1995) Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135
22. McCabe RP, Woody J, van Deventer SJH, Targan SR, et al (1996) A multicenter trial of cA2 anti TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 110:A962
23. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor α for Crohn's disease. N Engl J Med 337: 1029-1035
24. Rutgeerts P, D'Haens G, van Deventer SJH, Present DH, Mayer L, Hanauer SB, Braakman TAJ, DeWoody KL, Schaible TF, Targan SR (1997) Retreatment with anti-TNF-α chimeric antibody effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 112:A1078
25. Van Hogezand RA, van Deventer SJH, Present D, et al (1997) Controlled study of anti TNF α treatment for enterocutaneous fistulae complicating Crohn's disease. Gut 41 [Suppl 3]: A2, abstract no 01.11
26. D'Haens G, van Deventer S, van Hogezand R, Chalmers, et al (1998) Anti TNF α monoclonal antibody (cA2) produces endoscopic healing in patients with treatment resistant active Crohn's disease. Gastroenterology 114:A964
27. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Shaible TF, Shealy D, Geboes K, Rutgeerts PR (1999) Tumor necrosis factor α antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 116 (in press)
28. Stack WA, Mann SD, Heath P, et al (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor alpha in Crohn's disease. Lancet 349:521-524
29. Moreland LW, Baumgartner SW, Schiff MH, et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147